Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches

Summary

Summit Therapeutics is approaching a critical FDA approval decision, prompting an analyst upgrade to Hold rating. The article references an upcoming regulatory catalyst but lacks specific details about the drug, indication, or expected decision date.